Treatment Action Group is an independent AIDS research and policy think tank fighting for better treatment, a vaccine, and a cure for AIDS.
TAG works to ensure that all people with HIV receive lifesaving treatment, care, and information.
We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions.
TAG catalyzes open collective action by all affected communities, scientists, and policy makers to end AIDS.
Treatment Action Group
261 Fifth Avenue, Suite 2110
New York, NY 10016-7701
Categories Covered:Financial Issues, HIV Treatment and Medical Care, HIV-Related Policy Issues, HIV Prevention and Transmission, Anemia, Fatigue, and HIV, HIV Advocacy and Activism, TheBody en Español, Latinx People, Non-HIV Sexually Transmitted Infections, Physical Health Issues, Approved HIV Medications, Tools and Tips for HIV Advocacy, HIV Stigma and Discrimination, Regional/Global Anti-HIV Efforts, Tuberculosis and HIV, HIV in the Trump Era, HIV Advocates in the Spotlight, PrEP (HIV Pre-Exposure Prophylaxis), Cancer and HIV, HIV/AIDS Basics, Vaccines and Microbicides for HIV, HIV Drugs In Development, Norvir (Ritonavir), Switching or Stopping HIV Treatment, HIV/AIDS Outside the U.S., Finding HIV Support Groups and Services, Understanding HIV-Related Lab Tests, History of HIV/AIDS, African-Americans, Curing HIV, Gay Men, Mental Health, Substance Use and Harm Reduction for HIV
"The mind-boggling profits that Gilead earned since the launch of sofosbuvir could treat every person currently waiting for the hepatitis C cure while earning over US$16 billion in profits for shareholders."
"The policy moves made by the Trump administration, this year alone, have been illogical," Suraj Madoori writes.
Research indicates that robust universal health coverage could contribute to reducing HIV incidence by improving access to proven tools for reducing transmission.
Reining in prescription drug prices isn't so much a potential benefit of universal health care, but rather a factor in its affordability and success.
"Now is the time for us to engage in ongoing national conversations on a single-payer system that can potentially shift our current health care paradigm to one that is radically transformative, universal, cost-saving, and just for all people living w...
"Exportation of the insurance model to developing countries, especially at a time of global austerity, institutionalizes the retreat from the social contract at just the moment when investment in infectious diseases could result in the elimination of...
Trump's early tough talk on drug pricing is now a pro-industry, anti-regulation GOP dreamscape.
To support the efforts of prevention advocates across the U.S., Treatment Action Group has developed a series of modules to help support activists' capacity needs and to develop advocacy action plans.